|
|
February 2015 Pricing Sheet dated February 13, 2015 relating to Registration Statement No. 333-199966 Filed pursuant to Rule 433 |
|
STRUCTURED INVESTMENTS
Opportunities in U.S. Equities
Contingent Income Auto-Callable Securities due February 16, 2018
Based on the Performance of the Common Stock of Amgen Inc.
Principal at Risk Securities
|
PRICING TERMS – February 13, 2015 | ||||||
| Issuer: |
JPMorgan Chase & Co. | |||||
| Underlying stock: |
Common stock of Amgen Inc. | |||||
| Aggregate principal amount: |
$11,038,870 | |||||
| Early redemption: |
If, on any determination date (other than the final determination date), the closing price of the underlying stock is greater than or equal to the initial stock price, the securities will be automatically redeemed for an early redemption payment on the first contingent payment date immediately following the related determination date. No further payments will be made on the securities once they have been redeemed. | |||||
| Early redemption payment: |
The early redemption payment will be an amount equal to (i) the stated principal amount plus (ii) the contingent quarterly payment with respect to the related determination date. | |||||
| Contingent quarterly payment: |
— If, on any determination date, the closing price or the final stock price, as applicable, is greater than or equal to the downside threshold level, we will pay a contingent quarterly payment of $0.25 (2.50% of the stated principal amount) per security on the related contingent payment date. — If, on any determination date, the closing price or the final stock price, as applicable, is less than the downside threshold level, no contingent quarterly payment will be made with respect to that determination date. | |||||
| Determination dates: |
May 13, 2015, August 13, 2015, November 13, 2015, February 16, 2016, May 13, 2016, August 15, 2016, November 14, 2016, February 13, 2017, May 15, 2017, August 14, 2017, November 13, 2017 and February 13, 2018, subject to postponement for non-trading days and certain market disruption events. We also refer to February 13, 2018 as the final determination date. | |||||
| Contingent payment dates: |
With respect to each determination date other than the final determination date, the third business day after the related determination date. The payment of the contingent quarterly payment, if any, with respect to the final determination date will be made on the maturity date. | |||||
| Payment at maturity: |
— If the final stock price is greater than or equal to the downside threshold level: — If the final stock price is less than the downside threshold level: |
(i) the stated principal amount plus (ii) the contingent quarterly payment with respect to the final determination date (i) the cash value or (ii) at our option, a number of shares of the underlying stock equal to the exchange ratio as of the final determination date | ||||
| Cash value: |
The amount in cash equal to the stated principal amount times the closing price of one share of the underlying stock on the final determination date, divided by the initial stock price | |||||
| Exchange ratio: |
0.06516, which is the stated principal amount times the stock adjustment factor, divided by the initial stock price (subject to adjustment) | |||||
| Downside threshold level: |
$122.784, which is equal to 80% of the initial stock price | |||||
| Initial stock price: |
$153.48, which was the closing price of the underlying stock on the pricing date | |||||
| Final stock price: |
The closing price of the underlying stock on the final determination date | |||||
| Stock adjustment factor: |
The stock adjustment factor is referenced in determining the closing price of the underlying stock and is set initially at 1.0 on the pricing date. The stock adjustment factor is subject to adjustment in the event of certain corporate events affecting the underlying stock. | |||||
| Stated principal amount: |
$10 per security | |||||
| Issue price: |
$10 per security (see “Commissions and issue price” below) | |||||
| Pricing date: |
February 13, 2015 | |||||
| Original issue date (settlement date): |
February 19, 2015 | |||||
| Maturity date: |
February 16, 2018, subject to postponement in the event of certain market disruption events and as described under “General Terms of Notes — Postponement of a Payment Date” in the accompanying product supplement no. 4a-I | |||||
| CUSIP/ISIN: |
48127R479 / US48127R4790 | |||||
| Listing: |
The securities will not be listed on any securities exchange. | |||||
| Agent: |
J.P. Morgan Securities LLC (“JPMS”) | |||||
| Commissions and issue price: |
Price to public(1) | Fees and commissions | Proceeds to issuer | |||
| Per security |
$10 | $0.20(2) | $9.75 | |||
| $0.05(3) | ||||||
| Total |
$11,038,870 | $275,971.75 | $10,762,898.25 | |||
| (1) | See “Additional Information about the Securities — Supplemental use of proceeds and hedging” in the accompanying preliminary terms for information about the components of the price to public of the securities. |
| (2) | JPMS, acting as agent for JPMorgan Chase & Co., will pay all of the selling commissions of $0.20 per $10 stated principal amount security it receives from us to Morgan Stanley Smith Barney LLC. See “Plan of Distribution (Conflicts of Interest)” beginning on page PS-87 of the accompanying product supplement no. 4a-I. |
| (3) | Reflects a structuring fee payable to Morgan Stanley Wealth Management by the agent or its affiliates of $0.05 for each $10 stated principal amount security. |
The estimated value of the securities on the pricing date as determined by JPMS was $9.633 per $10 stated principal amount security. See “Additional Information about the Securities — JPMS’s estimated value of the securities” in the accompanying preliminary terms for additional information.
The securities are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank.
You should read this document together with the preliminary terms describing the offering and the related product supplement no. 4a-I, prospectus supplement and prospectus, each of which can be accessed via the hyperlinks below. Please also see “Additional Information about the Securities” in the accompanying preliminary terms.
Preliminary terms no. 306 dated February 6, 2015: http://www.sec.gov/Archives/edgar/data/19617/000089109215000971/e62680fwp.htm
Product supplement no. 4a-I dated November 7, 2014: http://www.sec.gov/Archives/edgar/data/19617/000089109214008407/e61359_424b2.pdf
Prospectus supplement and prospectus, each dated November 7, 2014: http://www.sec.gov/Archives/edgar/data/19617/000089109214008397/e61348_424b2.pdf
The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in this offering will arrange to send you the prospectus if you request it by calling toll-free (800) 869-3326.